When combined with your clinical history, metabolic markers, and state Medicaid policies, genetic insights can support a more informed conversation with your provider about which GLP-1 formulation (compounded semaglutide, tirzepatide, or other options) may align best with your individual biology
Hong, Z
Rx Only Takeda PRINCIPAL DISPLAY PANEL - Kit Carton - 3000 IU ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] NDC 0944-4628-01 Single-dose only For Intravenous Administration After Reconstitution Only Lyophilized powder for reconstitution ADYNOVATE and diluent preassembled in BAXJECT III system Rx Only Actual potency Takeda PRINCIPAL DISPLAY PANEL - Barrel Label - 3000 IU ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] For Intravenous Administration Only ADYNOVATE and diluent preassembled in BAXJECT III system Directions for use: see package insert Rx Only IU: LOT: EXP: Takeda 6521227 PRINCIPAL DISPLAY PANEL - Blister Label - 3000 IU ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] NDC 0944-4628-02 Single-dose only 6521500 For Intravenous Administration Only ADYNOVATE and diluent preassembled in BAXJECT III system Do not open until time of use Do not use if packaging is opened or damaged Discard unused portion
While the side effect of weight loss has been described as dose-dependent, with more weight loss seen with higher doses, never take more than the prescribed dose and under the medical advice of a healthcare professional, since higher doses result in a higher risk of unwanted side effects
Haematologica 2002;87:420-6
Learn how BPC-157 supports joint health with proven protocols
